Table 1.
FRDA Model | Neuroinflammatory Features | References |
---|---|---|
Patients | Increased glial activation in cerebellum and brainstem | [34] |
Increased ferritin signals in cerebellar microglia and astrocytes | [35] | |
Microglia with enlarged perikarya and thicker processes | [36] | |
Astroglia intrusion into dorsal roots | [37] | |
Hypertrophic cerebellar microglia positive for SOD1 enzyme | [38] | |
Increased GFAP plasma levels | [39] | |
KIKO mice | Increased cerebellar microgliosis and astrocytosis after LPS stimulation; increased oxidative damage and DNA repair proteins | [40] |
Increased cerebellar COX2 | [41] | |
YG8R mice | Increased cerebellar microglial activation after LPS; increased COX2 | [41] |
Increased satellite cell proliferation, astrocytosis and influx of OX42 positive cells in the spinal cord and cerebellum | [42] | |
FGKO mice | Severe ataxia after frataxin deletion in astrocytes during development | [43] |
Microglial cell lines | Increased DNA damage after frataxin knockdown | [40] |
Mouse primary astrocytes | Increased ROS production after frataxin knockdown | [44] |
Human astrocytes
in vitro |
Impaired mitochondrial activity and superoxide formation; increased release of inflammatory molecules and toxicity for neurons after frataxin knockdown | [45,46] |
iPSC-derived YG8R astrocytes | Reduced aconitase and DNA repair enzymes; increased sensitivity to oxidative stress | [45] |
Schwann cells
in vitro |
Decreased proliferation and increased inflammatory genes after frataxin knockdown | [11] |
Drosophila
melanogaster |
Locomotor dysfunction, brain degeneration and lipid metabolism defects after frataxin knockdown in glia | [47,48] |